A new therapeutic option in the management of allergic rhinitis

Allergic rhinitis (AR) affects both the quality of life and daily functioning of a patient. Carefully selected personalized therapy determines good management of disease symptoms. In the latest update of the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines, the algorithm for therapeutic management is based on the assessment of a patient’s condition with the use of a Visual Analogue Scale (VAS), therefore adopting an approach which involves either escalation (step up) or reduction (step down) of treatment. First-line drugs include: second-generation antihistamines, intranasal corticosteroids (INCS) and a combination of INCS with azelastine. Since the combination of INCS with intranasal H1 antihistamine drugs allows patients to benefit from therapeutic advantages of both drug categories, it is considered to be a universal treatment strategy. The combination of mometasone furoate with olopatadine hydrochloride is the latest therapeutic option in this drug category. These drugs prove highly effective and demonstrate a favorable safety profile